Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET t...
June 30 2021 - 5:47AM
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE:
TILS), a biotechnology company focused on innovative therapeutics
for oncology, inflammation and infectious diseases, announces an
interview with the Chairman of its’ Scientific Advisory Board and
Professor of Neurology at Harvard Medical School, Dr Howard Weiner
is to air on Bloomberg Markets with Matt Miller and Amanda Lang
today at 1.50pm ET/6.50pm BST.
About Tiziana Life Sciences
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK
biotechnology company that focuses on the discovery and development
of novel molecules to treat human disease in oncology and
immunology. In addition to Milciclib (a CDK inhibitor being
developed in oncology), the Company is also developing Foralumab in
COVID-19, multiple sclerosis, and Crohn’s Disease. Foralumab is the
only second generation fully human anti-CD3 monoclonal antibody in
clinical development in the world. This Phase 2 compound has
potential application in a wide range of autoimmune and
inflammatory diseases, such as nonalcoholic steatohepatitis (NASH),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The Company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammatory pulmonary diseases.
Forward-Looking StatementsCertain statements
made in this announcement are forward-looking statements. These
forward-looking statements are not historical facts but rather are
based on the Company's current expectations, estimates, and
projections about its industry; its beliefs; and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,'
'seeks,' 'estimates,' and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements. The Company cautions
security holders and prospective security holders not to place
undue reliance on these forward-looking statements, which reflect
the view of the Company only as of the date of this announcement.
The forward-looking statements made in this announcement relate
only to events as of the date on which the statements are made. The
Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect
events, circumstances, or unanticipated events occurring after the
date of this announcement except as required by law or by any
appropriate regulatory authority.
For further enquiries:
United Kingdom:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder+44 (0)20 7495 2379
United States:
Investors:
Dave Gentry, CEORedChip Companies
Inc.407-491-4498dave@redchip.com
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jul 2023 to Jul 2024